Literature DB >> 24425876

Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2-/- mice.

Shireesha Sankella1, Abhimanyu Garg, Jay D Horton, Anil K Agarwal.   

Abstract

In this study we examined the role of phosphatidic acid (PA) in hepatic glucose production (HGP) and development of hepatic insulin resistance in mice that lack 1-acylglycerol-3-phosphate O-acyltransferase 2 (AGPAT2). Liver lysophosphatidic acid and PA levels were increased ∼2- and ∼5-fold, respectively, in male Agpat2(-/-) mice compared with wild type mice. In the absence of AGPAT2, the liver can synthesize PAs by activating diacylglycerol kinase or phospholipase D, both of which were elevated in the livers of Agpat2(-/-) mice. We found that PAs C16:0/18:1 and C18:1/20:4 enhanced HGP in primary WT hepatocytes, an effect that was further enhanced in primary hepatocytes from Agpat2(-/-) mice. Lysophosphatidic acids C16:0 and C18:1 failed to increase HGP in primary hepatocytes. The activation of HGP was accompanied by an up-regulation of the key gluconeogenic enzymes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. This activation was suppressed by insulin in the WT primary hepatocytes but not in the Agpat2(-/-) primary hepatocytes. Thus, the lack of normal insulin signaling in Agpat2(-/-) livers allows unrestricted PA-induced gluconeogenesis significantly contributing to the development of hyperglycemia in these mice.

Entities:  

Keywords:  Gluconeogenesis; Insulin Resistance; Lipids; Lipodystrophy; Phosphatidic Acid

Mesh:

Substances:

Year:  2014        PMID: 24425876      PMCID: PMC3931038          DOI: 10.1074/jbc.M113.530998

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling.

Authors:  Chongben Zhang; Angela A Wendel; Matthew R Keogh; Thurl E Harris; Jie Chen; Rosalind A Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect.

Authors:  Mee-Sup Yoon; Yuting Sun; Edwin Arauz; Yu Jiang; Jie Chen
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

Review 3.  Clinical review#: Lipodystrophies: genetic and acquired body fat disorders.

Authors:  Abhimanyu Garg
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

4.  Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2(-/-) gene lipodystrophic mice.

Authors:  Anil K Agarwal; Suja Sukumaran; Víctor A Cortés; Katie Tunison; Dario Mizrachi; Shireesha Sankella; Robert D Gerard; Jay D Horton; Abhimanyu Garg
Journal:  J Biol Chem       Date:  2011-08-27       Impact factor: 5.157

5.  PDK1 protein phosphorylation at Thr354 by murine protein serine-threonine kinase 38 contributes to negative regulation of PDK1 protein activity.

Authors:  Hyun-A Seong; Haiyoung Jung; Ravi Manoharan; Hyunjung Ha
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

6.  NOX4 pathway as a source of selective insulin resistance and responsiveness.

Authors:  Xiangdong Wu; Kevin Jon Williams
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-02-09       Impact factor: 8.311

7.  Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy.

Authors:  Víctor A Cortés; David E Curtis; Suja Sukumaran; Xinli Shao; Vinay Parameswara; Shirya Rashid; Amy R Smith; Jimin Ren; Victoria Esser; Robert E Hammer; Anil K Agarwal; Jay D Horton; Abhimanyu Garg
Journal:  Cell Metab       Date:  2009-02       Impact factor: 27.287

8.  Reciprocal negative regulation of PDK1 and ASK1 signaling by direct interaction and phosphorylation.

Authors:  Hyun-A Seong; Haiyoung Jung; Hidenori Ichijo; Hyunjung Ha
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

9.  Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.

Authors:  Alfredo Toschi; Evan Lee; Limei Xu; Avalon Garcia; Noga Gadir; David A Foster
Journal:  Mol Cell Biol       Date:  2008-12-29       Impact factor: 4.272

Review 10.  Putting the pH into phosphatidic acid signaling.

Authors:  John J H Shin; Christopher J R Loewen
Journal:  BMC Biol       Date:  2011-12-02       Impact factor: 7.431

View more
  9 in total

1.  A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease.

Authors:  Arun J Sanyal; Tommy Pacana
Journal:  Trans Am Clin Climatol Assoc       Date:  2015

2.  Phosphatidic acid: a new therapeutic lead to suppress hepatic glucose production.

Authors:  Anil K Agarwal; Shireesha Sankella
Journal:  Diabetes Manag (Lond)       Date:  2014

Review 3.  Congenital generalized lipodystrophies--new insights into metabolic dysfunction.

Authors:  Nivedita Patni; Abhimanyu Garg
Journal:  Nat Rev Endocrinol       Date:  2015-08-04       Impact factor: 43.330

4.  Genome-wide analysis of hepatic lipid content in extreme obesity.

Authors:  Johanna K DiStefano; Christopher Kingsley; G Craig Wood; Xin Chu; George Argyropoulos; Christopher D Still; Stefania Cotta Doné; Christophe Legendre; Waibhav Tembe; Glenn S Gerhard
Journal:  Acta Diabetol       Date:  2014-09-23       Impact factor: 4.280

5.  AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue.

Authors:  Kelly M Cautivo; Carlos O Lizama; Pablo J Tapia; Anil K Agarwal; Abhimanyu Garg; Jay D Horton; Víctor A Cortés
Journal:  Mol Metab       Date:  2016-05-13       Impact factor: 7.422

6.  Lysophosphatidic acid counteracts glucagon-induced hepatocyte glucose production via STAT3.

Authors:  Evan P Taddeo; Stefan R Hargett; Sujoy Lahiri; Marin E Nelson; Jason A Liao; Chien Li; Jill K Slack-Davis; Jose L Tomsig; Kevin R Lynch; Zhen Yan; Thurl E Harris; Kyle L Hoehn
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

7.  Activation of Sphingolipid Pathway in the Livers of Lipodystrophic Agpat2-/- Mice.

Authors:  Shireesha Sankella; Abhimanyu Garg; Anil K Agarwal
Journal:  J Endocr Soc       Date:  2017-05-18

8.  AGPAT2 interaction with CDP-diacylglycerol synthases promotes the flux of fatty acids through the CDP-diacylglycerol pathway.

Authors:  Hoi Yin Mak; Qian Ouyang; Sergey Tumanov; Jiesi Xu; Ping Rong; Feitong Dong; Sin Man Lam; Xiaowei Wang; Ivan Lukmantara; Ximing Du; Mingming Gao; Andrew J Brown; Xin Gong; Guanghou Shui; Roland Stocker; Xun Huang; Shuai Chen; Hongyuan Yang
Journal:  Nat Commun       Date:  2021-11-25       Impact factor: 14.919

9.  Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells.

Authors:  Shireesha Sankella; Abhimanyu Garg; Anil K Agarwal
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.